Market news

On August 13, ADC Therapeutics (NYSE:ADCT) held its second-quarter earnings call and delivered a mixed message that investors are still sorting through. The company’s confirmatory trial for ZYNLONTA in second-line lymphoma cleared its main efficacy bar, but the FDA has flagged serious safety concerns about the combination that could complicate its path to a fuller […]

Motley Fool Press Release.

The central fair value estimate for ADC Therapeutics has been cut from US$5.00 to about US$3.33, which marks a sizeable reset in modeled upside for the stock. Analysts are linking these lower targets to mixed LOTIS-5 outcomes, a more cautious view on Zynlonta’s growth potential, and a wider debate on how much LOTIS-7 can offset current concerns. As you read on, you will see how this evolving narrative might shape expectations and what to watch next if you follow ADC Therapeutics. Analyst...

Detailed price information for Adc Therapeutics Sa (ADCT-N) from The Globe and Mail including charting and trades.

Detailed price information for Adc Therapeutics Sa (ADCT-N) from The Globe and Mail including charting and trades.

Moby summary of ADC Therapeutics S.A.'s Q2 2026 earnings call

ADC Therapeutics (NYSE:ADCT) reported second-quarter 2026 net product revenue of $18.6 million for ZYNLONTA, up from $18.1 million in the prior-year period, while executives said the treatment’s commercial performance remained broadly consistent with recent quarters. The company also said it is rea

ADC Therapeutics (ADCT) delivered earnings and revenue surprises of +42.11% and -4.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational updates.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.